Research & Education

Molecular Testing for Non-small Cell Lung Cancer: Introduction and 10 Most Important Questions

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. David Gandara covers the introduction and the 10 most important questions.

Molecular Testing for Non-small Cell Lung Cancer: How to obtain tissue and which tissue to obtain, and how to coordinate with pathology

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. Harvey Pass discusses how to obtain tissue, which tissue to obtain and how to coordinate with pathology.

Molecular Testing for Non-small Cell Lung Cancer: Treatment Decisions based on Molecular Findings

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. Gregory Riely covers treatment decisions based on molecular findings.

Molecular Testing for Non-small Cell Lung Cancer: Molecular Pathology

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. Ming Tsao discusses processing specimens and minimum requirements, tests for ALK and EGFR, and reporting and timing of results.

Molecular Testing for Non-small Cell Lung Cancer: Q&A

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. David Gandara takes questions from the audience and makes concluding comments.

Molecular Testing for Non-small Cell Lung Cancer: EGFR and ALK TKI therapy in advanced NSCLC

At the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, experts in molecular testing gathered to discuss critical questions in molecular testing for non-small cell lung cancer. In this segment, Dr. Paul Bunn covers molecular basis including when and why to stop or change course.

The new IASLC/ATS/ERS Lung Adenocarcinoma Classification - Module 1: Introduction

In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists.

The new IASLC/ATS/ERS Lung Adenocarcinoma Classification - Module 2: Implications

In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists.

The New IASLC/ATS/ERS Lung Adenocarcinoma Classification - Module 3: Highlights for the Pathologists

In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists.

The New IASLC/ATS/ERS Lung Adenocarcinoma Classification - Module 4: Highlights for the Radiologists

In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists.

Pages